E-viri
Recenzirano
-
Wu, Mei-Yi; Fu, Junjiang; Xiao, Xiuli; Wu, Jingbo; Wu, Ray-Chang
Cancer letters, 11/2014, Letnik: 354, Številka: 2Journal Article
Highlights • HDAC1 and HDAC7 are downstream effectors of miR-34a pathway in breast cancer. • Deacetylation of HSP70 K246 by HDAC1 and HDAC7 regulates therapy resistance. • Deacetylation of HSP70 K246 promotes therapy resistance by inhibiting autophagy. • The miR-34a–HDAC1/HDAC7–HSP70 K246 axis is a potential therapy resistant pathway.
